ABVC BioPharma's Affiliate OncoX Acquires Lycopenoid Platform, Signaling Growth in Oncology Sector

The acquisition of the Lycopenoid Lycogen® platform by OncoX BioPharma Inc., an affiliate of ABVC BioPharma, marks a significant step forward in the development of natural compound-based therapies for oncology and other sectors. Valued at approximately USD $4.06 million, this equity-based acquisition from Asia-Pacific Biotech Developing Inc. (APBDI) includes patented manufacturing technology and commercialization rights, setting the stage for potential revenue growth in the dermatology, oncology, and nutraceutical sectors.

Under the terms of the agreement, ABVC BioPharma stands to benefit from royalty payments as OncoX commercializes the Lycogen® platform. This arrangement exemplifies ABVC's strategy of generating non-dilutive revenue through affiliate-driven development. The Lycogen® platform, known for its next-generation lycopene-analog produced by microbial fermentation, has shown preclinical promise in cancer-related and metabolic disease models, highlighting its potential in targeted oncology indications.

The global oncology drug market, which surpassed USD $208 billion in 2023, is projected to grow to $484 billion by 2032, according to Precedence Research. The acquisition of the Lycogen® platform positions OncoX to tap into this expanding market, as well as the growing demand for lycopene-based ingredients, expected to exceed $170 million by 2029. This transaction not only enhances OncoX's commercialization capabilities but also reinforces ABVC's long-term growth strategy through strategic partnerships and clinical value creation.

Dr. Uttam Patil, ABVC Chief Executive Officer, emphasized the transaction's role in strengthening the company's pipeline and its ability to monetize platform assets. With the oncology drug market on a rapid growth trajectory and the increasing appeal of natural compounds in therapeutic applications, this acquisition could have far-reaching implications for the industry, offering new avenues for treatment and revenue generation.